<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------
FORM 8-K
--------------
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) November 22, 2000
-----------------
VION PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-26534 13-3671221
---------- --------- ------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
4 Science Park, New Haven, CT 06511
-------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (203) 498-4210
--------------
Not Applicable
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
ITEM 5. OTHER EVENTS
On November 22, 2000, Vion Pharmaceuticals, Inc. (the "Company") mailed
a notice to the holders of its outstanding shares of Class A Convertible
Preferred Stock, par value $.01 per share ("Class A Stock"), calling for the
redemption of such stocks on December 26, 2000 (the "Redemption Date") at a
redemption price of $10.00 per share. As of November 22, 2000, 1,950 shares of
Class A Stock were outstanding. The maximum amount of cash that would be
required for redemption of the Class A Stock would be $19,500.
A registered holder of Class A Stock shall have the right to convert
each share of Class A Stock into 2.777777 shares of the Company's Common Stock,
reflecting a current conversion price of $3.60 per share of Common Stock, prior
to the Redemption Date. The maximum number of shares of Common Stock which would
be issued if all outstanding shares of Class A Stock are converted prior to
redemption is 5,421. This right to convert the Class A Stock shall terminate at
5:00 p.m., New York City time, on the Redemption Date. After 5:00 p.m. New York
time on the Redemption Date the Class A Stock will no longer be convertible and
the holders will only have the right to receive the redemption price.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
VION PHARMACEUTICALS, INC.
Date: December 1, 2000 By: /s/ Alan Kessman
------------------------------------------
Name: Alan Kessman
Title: President and Chief Executive Officer
